Tie receptors: New modulators of angiogenic and lymphangiogenic responses

Nature Reviews Molecular Cell Biology

Volumn 2, Issue 4, 2001, Pages 257-267

  Jones, Nina ^a   Iljin, Kristiina ^b   Dumont, Daniel J ^a   Alitalo, Kari ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 1; CELL ADHESION MOLECULE; CELL SURFACE RECEPTOR; GROWTH PROMOTOR; MEMBRANE PROTEIN; MEN1 PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN TYROSINE KINASE; TIE RECEPTOR; TUMOR PROTEIN;

AGING; ANGIOGENESIS; ANIMAL; ANOXIA; BLOOD; CELL MOTION; CELL SURVIVAL; CYTOLOGY; HEMATOPOIESIS; HUMAN; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

AGING; ANGIOPOIETIN-1; ANIMALS; ANOXIA; CELL ADHESION MOLECULES; CELL MOVEMENT; CELL SURVIVAL; ENDOTHELIUM, VASCULAR; GROWTH SUBSTANCES; HEMATOPOIESIS; HUMANS; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CELL SURFACE; RECEPTORS, TIE; SIGNAL TRANSDUCTION;

EID: 0035318510     PISSN: 14710072     EISSN: None     Source Type: Journal    
DOI: 10.1038/35067005     Document Type: Review

References (107)

1. Witte, M. H., Way, D. L., Witte, C. L. & Bernas, M. Lymphangiogenesis: mechanisms, significance and clinical implications. EXS 79, 65-112 (1997).
2. Soker, S., Takashima, S., Miao, H. Q., Neufeld, G. & Klagsbrun, M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92, 735-745 (1998).
3. Jeltsch, M. et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 276, 1423-1425 (1997).
4. Karkkainen, M. J., Jussila, L., Ferrell, R. E., Finegold, D. N. & Alitalo, K. Molecular regulation of lymphangiogenesis and targets for tissue oedema. Trends Mol. Med. 7, 18-22 (2001).
5. Mandriota, S. J. et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J. 20, 672-682 (2001).
6. Stacker, S. A. et al. Vascular endothelial growth factor-D promotes the metastatic spread of cancer via the lymphatics. Nature Med. 7, 136-191 (2001).
7. Skobe, M. et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nature Med. 7, 192-198 (2001)
8. Karkkainen, M. J. et al. Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. Nature Genet. 25, 153-159 (2000).
9. Makinen, T. et al. Inhibition of lymphangiogenesis with resulting lymphoedema in transgenic mice expressing soluble VEGF receptor-3. Nature Med. 7, 199-205 (2001)
10. Davis, S. et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 87, 1161-1169 (1996). Description of the isolation of the first ligand for the Tie2 receptor using a new expression cloning technique.
11. Maisonpierre, P. C. et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277, 55-60 (1997). Shows that Ang2 is an antagonist of Tie2, providing the first evidence that related growth factors might have opposing actions towards receptor tyrosine kinases in vertebrates.
12. Valenzuela, D. M.et al. Angiopoietins 3 and 4: diverging gene counterparts in mice and humans. Proc. Natl Acad. Sci. USA 96, 1904-1909 (1999).
13. Shalaby, F. et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376, 62-66 (1995).
14. Fong, G. H., Rossant, J., Gertsenstein, M. & Breitman, M. L. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376, 66-70 (1995).
15. Dumont, D. J. et al. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev. 8, 1897-1909 (1994). Description of the importance of Tie2 in regulating the survival and integrity of the endothelium during development.
16. Sato, T. N. et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 376, 70-74 (1995). Describes the importance of Tiel and Tie2 in vascular integrity and remodelling during embryogenesis, respectively.
17. Suri, C. et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87, 1171-1180 1996). Shows that Ang1-deficient mice have a similar phenotype to Tie2-deficient mice and implies that Ang1 is required for endothelial-periendothelial paracrine communication during vascular development.
18. Patan, S. TIE1 and TIE2 receptor tyrosine kinases inversely regulate embryonic angiogenesis by the mechanism of intussusceptive microvascular growth. Microvasc. Res. 56, 1-21 (1998).
19. Puri, M., Rossant, J., Alitalo, K., Bernstein, A. & Partanen, J. The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells. EMBO J. 14, 5884-5891 (1995). Describes the essential role of Tie1 in controlling the integrity of the embryonic microvascular endothelium.
20. Puri, M. C., Partanen, J., Rossant, J. & Bernstein, A. Interaction of the TEK and TIE receptor tyrosine kinases during cardiovascular development. Development 126, 4569-4580 (1999). Shows that the functions mediated by the Tie1 and Tie2 receptors are not redundant through analysis of chimeric embryos. An interesting endocardial developmental phenotype is also revealed.
21. Partanen, J. et al. Cell autonomous functions of the receptor tyrosine kinase TIE in a late phase of angiogenic capillary growth and endothelial cell survival during murine development. Development 122, 3013-3021 (1996).
22. Suri, C. et al. Increased vascularization in mice overexpressing angiopoietin-1. Science 282, 468-471 (1998).
23. Thurston, G. et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 286, 2511-2514 (1999). Shows that Ang1 can block vascular permeability induced by VEGF.
24. Jones, N. et al. Rescue of the early vascular defects in Tek/Tie2 null mice reveals an essential survival function. EMBO Rep. (in the press).
25. Wong, A. L et al. Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues. Circ. Res. 81, 567-574 (1997).
26. Alon, T. et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nature Med. 1, 1024-1028 (1995).
27. Benjamin, L. E., Hemo, I. & Keshet, E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 125, 1591-1598 (1998).
28. Holash, J, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284, 1994-1998 (1999). Shows that Ang2 is associated with tumour angiogenesis in a model where the tumour co-opts existing host vessels.
29. Stratmann, A., Risau, W. & Plate, K. H. Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am. J. Pathol. 153, 1459-1466 (1998).
30. Zagzag, D. et al. In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker of tumor angiogenesis. Exp. Neurol. 159, 391-400 (1999).
31. Brown, L. F., Dezube, B. J., Tognazzi, K., Dvorak, H. F. & Yancopoulos, G. D. Expression of Tie1, Tie2, and angiopoietins 1,2, and 4 in Kaposi's sarcoma and cutaneous angiosarcoma. Am. J. Pathol. 156, 2179-2183 (2000).
32. Asahara, T. et al. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ. Res. 83, 233-240 (1998).
33. Teichert-Kuliszewska, K. et al. Biological actions of angiopoietin-1 and-2 in a fibrin matrix model of angiogenesis. Cardiovasc. Res. 49, 659-670 (2001).
34. Kim, I. et al. Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Oncogene 19, 4549-4552 (2000).
35. Vikkula, M, et al. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell 87, 1181-1190 (1996). Finds an activating mutation in the Tie2 kinase domain associated with venous malformations in two unrelated families.
36. Carvert, J. T. et al. Allelic and locus heterogeneity in inherited venous malformations. Hum. Mol. Genet. 8, 1279-1289 (1999).
37. Korpelainen, E. I., Karkkainen, M., Gunji, Y., Vikkula, M. & Alitalo, K. Endothelial receptor tyrosine kinases activate the STAT signaling pathway: mutant Tie-2 causing venous malformations signals a distinct STAT activation response. Oncogene 18, 1-8 (1999).
38. Kaipainen, A. et al. Enhanced expression of the tie receptor tyrosine kinase messenger RNA in the vascular endothelium of metastatic melanomas. Cancer Res. 54, 6571-6577 (1994).
39. Hatva, E. et al. Expression of endothelial cell-specific receptor tyrosine kinases and growth factors in human brain tumors. Am. J. Pathol. 146, 368-378 (1995).
40. Salven, P. et al. Endothelial Tie growth factor receptor provides antigenio marker for assessment of breast cancer angiogenesis. Br. J. Cancer 74, 69-72 (1996).
41. Peters, K. G. et al. Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis. Br. J. Cancer 77, 51-56 (1998).
42. Korhonen, J. et al. Enhanced expression of the tie receptor tyrosine kinase in endothelial cells during neovascularization. Blood 80, 2548-2555 (1992).
43. Kukk, E. et al. Analysis of Tie receptor tyrosine kinase in haemopoietic progenitor and leukaemia cells. Br. J. Haematol. 98, 195-203 (1997).
44. Oh, H. et al. Hypoxia and vascular endothelial growth factor selectively up-regulate angiopoietin-2 in bovine microvascular endothelial cells. J. Biol. Chem. 274, 15732-15739 (1999).
45. Mandriota, S. J. & Pepper. M. S. Regulation of angiopoietin-2 mRNA levels in bovine microvascular endothelial cells by cytokines and hypoxia. Circ. Res. 83, 852-859 (1998).
46. McCarthy, M. J., Crowther, M., Bell, P. R. & Brindle, N. P. The endothelial receptor tyrosine kinase tie-1 is upregulated by hypoxia and vascular endothelial growth factor. FEBS Lett. 423, 334-338 (1998).
47. Tian, H., McKnight, S. L & Russell, D. W. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev. 11, 72-82 (1997).
48. Willam, C. et al. Tie2 receptor expression is stimulated by hypoxia and proinflammatory cytokines in human endothelial cells. Circ. Res. 87, 370-377 (2000).
49. Schlaeger, T. M. et al. Uniform vascular-endothelial-cell-specific gene expression in both embryonic and adult transgenic mice. Proc. Natl Acad. Sci. USA 94, 3058-3063 (1997).
50. Iljin, K. et al. Role of ets factors in the activity and endothelial cell specificity of the mouse Tie gene promoter. FASEB J. 13, 377-386 (1999).
51. Lin, P. et al. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc. Natl Acad. Sci. USA 95, 8829-8834 (1998).
52. Lin, P. et al. Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth. J. Clin. Invest. 100, 2072-2078 (1997). References 51 and 52 indicate that Tie2 might be useful in tumour therapy.
53. Siemeister, G. et al. Two independent mechanisms essential for tumor angiogenesis: inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway. Cancer Res. 59, 3185-3191 (1999).
54. Millauer, B., Shawver, L K., Plate, K. H., Risau, W. & Ullrich, A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367, 576-579 (1994).
55. Huang, L. Turck, C. W., Rao, P. & Peters, K. G. GRB2 and SH-PTP2: potentially important endothelial signaling molecules downstream of the TEK/TIE2 receptor tyrosine kinase. Oncogene 11, 2097-2103 (1995).
56. Jones, N. et al. Identification of Tek/Tie2 binding partners. Binding to a multifunctional docking site mediates cell survival and migration. J. Biol. Chem. 274, 30896-30905 (1999).
57. Koblizek, T. I., Weiss, C., Yancopoulos, G. D., Deutsch, U. & Risau, W. Angiopoietin-1 induces sprouting angiogenesis in vitro. Curr. Biol. 8, 529-532 (1998).
58. Witzenbichler, B., Maisonpierre, P. C., Jones, P., Yancopoulos, G. D. & Isner, J. M. Chemotactic properties of angiopoietin-1 and -2, ligands for the endothelial-specific receptor tyrosine kinase Tie2. J. Biol. Chem. 273, 18514-18521 (1998).
59. Kwak, H. J., So, J. N., Lee, S. J., Kimn, I. & Koh, G. Y. Angiopoietin-1 is an apoptosis survival factor for endothelial cells. FEBS Lett. 448, 249-253 (1999).
60. Kontos, C. D. et al. Tyrosine 1101 of Tie2 is the major site of association of p85 and is required for activation of phosphatidylinositol 3-kinase and Akt. Mol. Cell Biol. 18, 4131-4140 (1998).
61. Fujikawa, K., de Aos Scherpenseel, I., Jain, S. K., Presman, E. & Varticovski, L Role of P13-kinase in angiopoietin-1-mediated migration and attachment-dependent survival of endothelial cells. Exp. Cell Res. 253, 663-672 (1999).
62. Kim, I. et al. Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Circ. Res. 86, 24-29 (2000).
63. Hayes, A. J. et al. Angiopoietin-1 and its receptor tie-2 participate in the regulation of capillary-like tubule formation and survival of endothelial cells. Microvasc. Res. 58, 224-237 (1999).
64. Papapetropoulos, A. et al. Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors. Lab. Invest. 79, 213-223 (1999).
65. Jiang, B. H., Zheng, J. Z., Aoki, M. & Vogt, P. K. Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc. Natl Acad. Sci. USA 97, 1749-1753 (2000).
66. Papapetropoulos, A. et al. Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J. Biol. Chem. 275, 9102-9105 (2000).
67. Speliotes, E. K., Uren, A., Vaux. D. & Horvitz, H. R. The survivin-like C. elegans BIR-1 protein acts with the Aurora-like kinase AIR-2 to a7ffect chromosomes and the spindle midzone. Mol. Cell 6, 211-223 (2000).
68. Gerber, H. P. et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J. Biol. Chem. 273, 30336-30343 (1998).
69. Kim, I. et al. Angiopoietin-1 induces endothelial cell sprouting through the activation of focal adhesion kinase and plasmin secretion. Circ. Res. 86, 952-959 2000).
70. Jones, N. & Dumont, D. J. The Tek/Tie2 receptor signals through a novel Dok-related docking protein, Dok-R. Oncogens 17, 1097-1108 (1998).
71. Huang, L. et al. HCPTPA, a protein tyrosine phosphatase that regulates vascular endothelial growth factor receptor-mediated signal transduction and biological activity. J. Biol. Chem. 274, 38183-38188 (1999).
72. Fachinger, G., Deutsch, U. & Risau, W. Functional interaction of vascular endothelial-protein-tyrosine phosphatase with the angiopoietin receptor tie-2. Oncogene 18, 5948-5953 (1999).
73. Shewchuk, L M. et al. Structure of the Tie2 RTK domain. Self-inhibition by the nucleotide binding loop, activation loop, and C-terminal tail. Struct. Fold Des. 8, 1105-1113 (2001).
74. Yabkowitz, R. et a/. Regulation of tie receptor expression on human endothelial cells by protein kinase C-mediated release of soluble tie. Blood 90, 706-715 (1997).
75. McCarthy, M. J. et al. Potential roles of metalloprotease mediated ectodomain cleavage in signaling by the endothelial receptor tyrosine kinase Tie-1. Lab. Invest. 79, 889-895 (1999).
76. Yabkowitz, R. et al. Inflammatory cytokines and vascular endothelial growth factor stimulate the release of soluble tie receptor from human endothelial cells via metalloprotease activation. Blood 93, 1969-1979 (1999).
77. Marron, M. B., Hughes, D. P., McCarthy, M. J., Beaumont, E. R. & Brindle, N. P. Tie-1 receptor tyrosine kinase endodomain interaction with SHP2: potential signalling mechanisms and roles in angiogenesis. Adv. Exp. Med. Biol. 476, 35-46 (2000).
78. Marron, M. B., Hughes, D. P., Edge, M. D., Forder, C. L. & Brindle, N. P. Evidence for heterotypic interaction between the receptor tyrosine kinases tie-1 and tie-2. J. Biol. Chem. 275, 39741-39746 (2000).
79. Thurston, G. et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nature Med. 6, 460-463 (2000).
80. Partanen, J. et al. A novel endothelial cell surface receptor tyrosine kinase with extracellular epidermal growth factor homology domains. Mol. Cell. Biol. 12, 1698-1707 (1992).
81. Dumont, D. J., Gradwohl, G. J., Fong, G. H., Auerbach, R. & Breitman, M. L. The endothelial-specific receptor tyrosine kinase, tek, is a member of a new subfamily of receptors. Oncogene 8, 1293-1301 (1993).
82. Gerber, H. P. et al. VEGF is required for growth and survival in neonatal mice. Development 126, 1149-1159 (1999).
83. Gerber, H. P. et al. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nature Med. 5, 623-628 (1999).
84. Ferrara, N. et al. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nature Med. 4, 336-340 1998).
85. Pe'er, J. et al. Upregulated expression of vascular endothelial growth factor in proliferative diabetic retinopathy. Br. J. Ophthalmol. 80, 241-245 (1996).
86. Iwama, A. et al. Molecular cloning and characterization of mouse TIE and TEK receptor tyrosine kinase genes and their expression in hematopoietic stem cells. Biochem. Biophys. Res. Commun. 195, 301-309 (1993).
87. Rodewald, H. R. & Sato, T. N. Tie1, a receptor tyrosine kinase essential for vascular endothelial cell integrity, is not critical for the development of hematopoietic cells. Oncogene 12, 397-404 (1996).
88. Takakura, N. et al. Critical role of the TIE2 endothelial cell receptor in the development of definitive hematopoiesis. Immunity 9, 677-686 (1998). Associates Tie2 with the regulation of haematopoiesis.
89. Takakura, N. et al. A role for hematopoietic stem cells in promoting angiogenesis. Cell 102, 199-209 (2001).
90. Carmeliet, P. et al. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 98, 147-157 (1999).
91. Wiesener, M. S. et al. Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1α. Blood 92, 2260-2268 (1998).
92. Claffey, K. P. et al. Identification of a human VPF/VEGF 3 ′ untranslated region mediating hypoxia-induced mRNA stability. Mol. Biol. Cell 9, 469-481 (1998).
93. Maltepe, E., Schmidt, J. V. Baunoch, D., Bradfield, C. A. & Simon, M. C. Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT. Nature 386, 403-407 (1997).
94. Ryan, H. E., Lo, J. & Johnson, R. S. HIF-1α is required for solid tumor formation and embryonic vascularization. EMBO J. 17, 3005-3015 (1998).
95. Peng, J., Zhang, L. Drysdale, L & Fong, G. H. The transcription factor EPAS-1/hypoxia-inducible factor 2α plays an important role in vascular remodeling. Proc. Natl Acad. Sci. USA 97, 8386-8391 (2000).
96. Ravi, R. et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α. Genes Dev. 14, 34-44 (2000).
97. Carmeliet, P. et a/. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394, 485-490 (1998).
98. Maxwell, P. H. et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271-275 (1999).
99. Lisztwan, J., Imbert, G., Wirbelauer, C., Gstaiger, M. & Krek, W. The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Den 13, 1822-1833 (1999).
100. Graeber, T. G. et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379, 88-91 (1996).
101. Procopio, W. N., Pelavin, P. I., Lee, W. M. & Yeilding, N. M. Angiopoietin-1 and-2 coiled coil domains mediate distinct homo-oligomerization patterns, but fibrinogen-like domains mediate ligand activity. J. Biol. Chem. 274, 30195-30201 (1999).
102. Huang, Y. Q., U, J. J. & Kaipatkin, S. Identification of a family of alternatively spliced mRNA species of angiopoietin-1. Blood 95, 1993-1999 (2000).
103. Kim, I. et al. Characterization and expression of a novel alternatively spliced human angiopoietin-2. J. Biol. Chem. 275, 18550-18556 (2000).
104. Mezquita, J., Mezquita, B., Pau, M. & Mezquita, C. Characterization of a novel form of angiopoietin-2 (Ang-2B) and expression of VEGF and angiopoietin-2 during chicken testicular development and regression. Biochem. Biophys. Res. Commun. 260, 492-498 (1999).
105. Korhonen, J. et al. Endothelial-specific gene expression directed by the tie gene promoter in vivo. Blood 86, 1828-1835 (1995).
106. Schlaeger, T. M., Qin, Y., Fujiwara, Y., Magram, J. & Sato, T. N. Vascular endothelial cell lineage-specific promoter in transgenic mice. Development 121, 1089-1098 (1995).
107. Jones, N. & Dumont, D. J. Recruitment of Dok-R to the EGF receptor through its PTB domain is required for attenuation of Erk MAP kinase activation. Curr. Biol. 9, 1057-1060 (1999).